HIV / AIDS in the News

Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV-1 treatment meets primary endpoint in Phase 3 ARTISTRY-1 trial - European AIDS Treatment Group

 

Highlights from The Liver Meeting 2025 - European AIDS Treatment Group

 

Vanderbilt Institute for Global Health marks 20 years - VUMC News

 

History of the AIDS Crisis: A Timeline - Britannica

 

In under a year, Trump administration has threatened decades of progress in global fight against HIV/AIDS - prismreports.org

 

Unsuspected drug shortage is impacting the German HIV PrEP supply - results of a cross-sectional survey show: majority of PrEP users had to stop or switch to on-demand PrEP and higher unmet PrEP demand among women, diverse individuals, and those in - BMC…

 

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial - Gilead Sciences (NASDAQ:GILD) - Benzinga

 

Gilead stock rises after positive HIV treatment trial results - Investing.com

 

Watch ‘Still Here,’ A Short Documentary About HIV And Aging - inmagazine.ca

 

Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects - TipRanks

 

Maui AIDS Foundation to host Transgender Day of Remembrance and World AIDS Day - Maui Now

 

Accused rapist wanted to give men HIV, court hears - Yahoo News New Zealand

 

Accused Washington rapist meant to give men HIV, court hears - BBC

 

Accused Washington rapist meant to give men HIV, court hears - BBC

 

Gilead hits late-stage trial win for new HIV therapy (GILD) - Seeking Alpha

 

Gilead hits late-stage trial win for new single-tablet HIV therapy - Seeking Alpha

 

Single Tablet HIV Combination Therapy Demonstrates Noninferiority When Switched From Multi-Tablet Regimens - Contagion Live

 

Atlanta mourns the loss of HIV activist Dr. Alvan Quamina - Rough Draft Atlanta

 

Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings - Fierce Pharma

 

Gilead (GILD) Reveals Promising Phase 3 Trial Results for HIV Tr - GuruFocus

 

Gilead Reports Positive Phase 3 Results For Bictegravir/ Lenacapavir Single-tablet Regimen For HIV - Nasdaq

 

Monroe man accused of intentionally exposing others to HIV - hannapub.com

 

Gilead says single-tablet option matches complex HIV regimens in Phase III study - FirstWord Pharma

 

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial - Yahoo Finance

 

Iron Absorption and Supplementation in HIV-Positive Children - Bioengineer.org

 

Anal cancer, HIV, gay men, what you need to know - Q Voice News

 

Daniel Garza uses comedy to discuss gay sex, anal cancer - Q Voice News

 

Bictegravir-based regimens increasingly used for HIV PEP in the United States - European AIDS Treatment Group

 

AIDS Monument ready to tell its ‘stories’ - Beverly Press & Park Labrea News

 

Factors Influencing Georgia’s HIV Healthcare Providers’ Attitudes - Bioengineer.org